Schizophrenie – eine milde Enzephalitis?

K. Bechter

doi:10.1055/s-0033-1335253

Fortschritte der Neurologie · Psychiatrie, Table of Contents

Fortschr Neurol Psychiatr 2013; 81(5): 250-259
DOI: 10.1055/s-0033-1335253

Übersicht

Schizophrenie – eine milde Enzephalitis?

Schizophrenia – a Mild Encephalitis?

K. Bechter

Abstract

Zusammenfassung

Die Milde-Enzephalitis (ME)-Hypothese beschreibt eine Subgruppe schwerer psychiatrischer Erkrankungen, insbesondere eine Subgruppe von Schizophrenien, bei denen Kern der Pathogenese eine geringfügige Neuroinflammation darstellt. Low Level Neuroinflammation wird in der experimentellen Neuroimmunologie zunehmend beschrieben und kann prinzipiell verschiedenartige Psychopathologien erklären. Epidemiologie und Krankheitsverlauf von Schizophrenien sind gut kompatibel mit der ME-Hypothese, was bedeuten könnte, dass eine relativ große Subgruppe mit ME assoziiert ist. Zum ME-Modell gehören folgende wesentliche Bedingungsfaktoren: Gene, Umweltfaktoren (hierbei insbesondere infektiöse Erreger) und Immunsystem. Die Typizität der beim Individuum auftretenden Symptomatik mag wesentlich auf anderen Bedingungsfaktoren, z. B. präexistierenden Vulnerabilitäten beruhen. Die erste Large Scale Epidemiological Study der Psychiatrie identifizierte schwere Infektionskrankheiten und Autoimmunkrankheiten, welche im Laufe des Lebens auftreten, als Risikofaktoren. Dies und klinische Befunde unterstützen zunehmend die ME-Hypothese, z. B. aktivierte Monozyten oder Proteomveränderungen im Blut und diskrete Liquorpathologien in über 60 % therapieresistenter schizophrener Psychosen oder aktivierte Mikroglia und Dyskonnektivität in bildgebenden Verfahren.

Abstract

The mild encephalitis (ME) hypothesis describes a subgroup of severe psychiatric disorders, with a focus on a subgroup of schizophrenias, in which low-level neuroinflammation (LLNI) represents the core in pathogenesis. LLNI is increasingly recognised in experimental neuroimmunology and is in principle able to explain various types of psychopathology. Epidemiology and course of schizophrenia are well compatible with the ME hypothesis, indirectly indicating that the ME subgroup may be rather large. With the ME model connected is a set of three contributing factors: genes, environment (especially infectious agents) and the immune system. The type of psychopathology observed in the individual case may heavily depend upon other conditions, e. g. pre-existing vulnerabilities. The first large-scale epidemiological study in psychiatry identified two factors during lifetime, severe infectious diseases and autoimmune diseases, as risk factors. This and clinical findings more and more support the ME hypothesis, e. g., activated monocytes or proteome changes in blood and slight CSF pathologies in more than 60 % of therapy-resistant schizophrenia, or activated microglia and dysconnectivity in neuroimaging.

Schlüsselwörter

Low Level Neuroinflammation - milde Enzephalitis - Liquor cerebrospinalis - Schizophrenie

Key words

low-level neuroinflammation - mild encephalitis - cerebrospinal fluid (CSF) - schizophrenia

Full Text

References

Literatur
1 Bechter K. „Mild Encephalitis“ – Brain-Organic Pathologies between Neurologic and Psychiatric Disease. Neurol Psychiatry Brain Res 2009; 16 (Suppl. 01) 5-6
2 Bechter K. Diagnosis of infectious or inflammatory psychosyndromes. The Open Neurology Journal 2012; 6 (Suppl. 01) 113-118
3 Schmitt A et al. Reduction of gyrification index in the cerebellar vermis in schizophrenia: a post-mortem study. World J Biol Psychiatry 2011; 12 (Suppl. 01) 99-103
4 Swedo SE et al. Streptococcal infection, Tourette syndrome, and OCD: is there a connection? PANDAS: horse or zebra?. Neurology 2010; 74: 1397-1398 author reply 1398-1399
5 Bechter K et al. Therapy-resistant depression with fatigue. A case of presumed streptococcal-associated autoimmune disorder. Nervenarzt 2007; 78 : 338: 340-341
6 Huber G. Klinik und Psychopathologie der organischen Psychosen. In: Kisker KP, et al. (ed) Psychiatrie der Gegenwart. Berlin Heidelberg New York: Springer; 1972: 71-146
7 Bonhoeffer K. Die exogenen Reaktionstypen. Arch Psychiat Nervenkr 1917; 58: 58-70
8 Blazer DG, van Nieuwenhuizen AO. Evidence for the diagnostic criteria of delirium: an update. Curr Opin Psychiatry 2012; 25: 239-243
9 Coid JW. Aetiological risk factors for personality disorders. Br J Psychiatry 1999; 174: 530-538
10 Raeder MB et al. Arachnoid cysts cause cognitive deficits that improve after surgery. Neurology 2005; 64: 160-162
11 Bechter K et al. Personality disorders improved after arachnoid cyst neurosurgery, then rediagnosed as “minor” organic personality disorders. Psychiatry Res 2010; 184: 196-200
12 Propping P. (ed). Psychiatrische Genetik. Befunde und Konzepte. Heidelberg: Springer Verlag GmbH; 1989
13 Lesch KP, Waider J. Serotonin in the modulation of neural plasticity and networks: implications for neurodevelopmental disorders. Neuron 2012; 76: 175-191
14 Irani SR, Vincent A. Autoimmune encephalitis – new awareness, challenging questions. Discov Med 2011; 11: 449-458
15 Dalmau J, Bataller L. Clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic neurologic disorders. Hematol Oncol Clin North Am 2006; 20: 1319-1335
16 Pedrosa DJ et al. Anti-NMDA receptor encephalitis: a neurological and psychiatric emergency. Fortschr Neurol Psychiatr 2012; 80: 29-35
17 Steiner J et al. Increased Prevalence of Diverse N-Methyl-D-Aspartate Glutamate Receptor Antibodies in Patients With an Initial Diagnosis of Schizophrenia: Specific Relevance of IgG NR1a Antibodies for Distinction From N-Methyl-D-Aspartate Glutamate Receptor Encephalitis. JAMA Psychiatry 2013; 70: 271-278
18 Meyding-Lamadé U, Bechter K. Meningoencephalitiden als Ursache psychiatrischer Syndrome – Psychisch krank durch Mikroben im Hirn. InFo Neurologie & Psychiatrie 2005; 7: 38-45
19 Gross G, Huber G, Linz M. Zur Frage der symptomatischen Schizophrenie und Zyklothymie. Zbl Neurol 1989; 251: 323-332
20 Huber G. Zur nosologischen Differenzierung lebensbedrohlicher katatoner Psychosen. Schweiz. Arch Neurol Psychiatrie 1955; 74: 216-244
21 Bechter K. Basic symptoms in symptomatic schizophrenia. Neurol Psychiatry Brain Res 2002; 10: 35-40
22 Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol 2007; 20: 732-737
23 Irani S, Lang B. Autoantibody-mediated disorders of the central nervous system. Autoimmunity 2008; 41: 55-65
24 Anderson NE, Barber PA. Limbic encephalitis – a review. J Clin Neurosci 2008; 15: 961-971
25 Lancaster E, Dalmau J. Neuronal autoantigens pathogenesis – associated disorders and antibody testing. Nat Rev Neurol 2012; 8: 380-390
26 Lennox BR, Coles AJ, Vincent A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry 2012; 200: 92-94
27 Glaser CA et al. Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin Infect Dis 2006; 43: 1565-1577
28 Wildemann B, Oschmann P, Reiber H (eds). Laboratory Diagnosis in Neurology. Stuttgart: Thieme; 2010
29 Osborn AG, Salzman KL, Barkovich AJ (eds). Diagnostic Imaging: Brain. Lippincott Williams & Wilkins; 2010
30 Johnson RT. (ed). Viral infections of the nervous system. New York.: Raven; 1982
31 Aurelius E. Herpes simplex encephalitis. Early diagnosis and immune activation in the acute stage and during long-term follow-up. Scand J Infect Dis Suppl 1993; 89: 3-62
32 Bechter K, Hodgkiss A. Research strategies in “slow” infections in psychiatry. Hist Psychiatry 1995; 6: 503-511
33 Torrey EF, Yolken RH. Schizophrenia and toxoplasmosis. Schizophr Bull 2007; 33: 727-728
34 Nathan C. Points of control in inflammation. Nature 2002; 420: 846-852
35 Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-435
36 O’Callaghan JP, Sriram K, Miller DB. Defining “neuroinflammation”. Ann N Y Acad Sci 2008; 1139: 318-330
37 Swedo SE et al. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am J Psychiatry 1998; 155: 264-271
38 Bechter K et al. Therapieresistente Depression mit Fatigue. Fall einer vermutlichen streptokokkenassoziierten Autoimmunkrankheit. Nervenarzt 2007; 78: 338, 340-341
39 Kramer K et al. TNF-Overexpression in Borna Disease Virus-Infected Mouse Brains Triggers Inflammatory Reaction and Epileptic Seizures. PLoS One 2012; 7: e41476
40 Bechter K. Mild encephalitis underlying psychiatric disorder – A reconsideration and hypothesis exemplified on Borna Disease. Neurol Psychiatry Brain Res 2001; 9: 55-70
41 Bechter K, Schuttler R, Herzog S. Borna disease virus: possible causal agent in psychiatric and neurological disorders in two families. Psychiatry Res 1992; 42: 291-294
42 Hafner H. Epidemiology of schizophrenia. The disease model of schizophrenia in the light of current epidemiological knowledge. Eur Psychiatry 1995; 10: 217-227
43 Herzog S et al. Molecular characterization of Borna disease virus from naturally infected animals and possible links to human disorders. Arch Virol Suppl 1997; 13: 183-190
44 Dean B. Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies. Int J Neuropsychopharmacol 2010; 14: 997-1012
45 Horie M et al. Endogenous non-retroviral RNA virus elements in mammalian genomes. Nature 2010; 463: 84-87
46 Belyi VA, Levine AJ, Skalka AM. Unexpected inheritance: multiple integrations of ancient bornavirus and ebolavirus/marburgvirus sequences in vertebrate genomes. PLoS Pathog 2010; 6: e1001030
47 Dalman C et al. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am J Psychiatry 2008; 165: 59-65
48 Eaton WW et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 2006; 163: 521-528
49 Benros ME, Mortensen PB, Eaton WW. Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci 2012; 1262: 56-66
50 McGrath J et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008; 30: 67-76
51 Zammit S et al. Individuals, schools, and neighborhood: a multilevel longitudinal study of variation in incidence of psychotic disorders. Arch Gen Psychiatry 2010; 67: 914-922
52 van Os J, Kenis G, Rutten BP. The environment and schizophrenia. Nature 2010; 468: 203-212
53 Kirkbride JB et al. Incidence of schizophrenia and other psychoses in England, 1950–2009: A systematic review and meta-analyses. PLOS ONE 2012; 7: e1660
54 Benros M et al. Autoimmune diseases and severe infections as risk factors for schizophrenia – A 30-year population-based register study. Am J Psychiatry 2011; 168: 1303-1310
55 Ackerknecht EH. Causes and pseudocauses in the history of diseases. in Stevenson LG, (ed) A celebration of medical history. Baltimore, London.: Johns Hopkins University Press; 1982: 19-31
56 Uher R. The role of genetic variation in the causation of mental illness: an evolution-informed framework. Mol Psychiatry 2009; 14: 1072-1082
57 Caspi A et al. Genetic sensitivity to the environment: the case of the serotonin transporter gene and its implications for studying complex diseases and traits. Am J Psychiatry 2010; 167: 509-527
58 Graham AL et al. Fitness correlates of heritable variation in antibody responsiveness in a wild mammal. Science 2010; 330: 662-665
59 Bechter K. Updating the Mild Encephalitis Hypothesis of Schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 71-91
60 Stefansson H et al. Common variants conferring risk of schizophrenia. Nature 2009; 460: 744-747
61 Raison CL, Miller AH. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry 2013; 18: 15-37
62 Kornhuber HH, Kornhuber J. A neuroimmunological challenge: schizophrenia as an autoimmune disease. Arch Ital Biol 1987; 125: 271-272
63 Fathman CG et al. An array of possibilities for the study of autoimmunity. Nature 2005; 435: 605-611
64 Drexhage RC et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010; 10: 59-76
65 Conrad K. The predictive relevance of autoantibodies. in Conrad K, et al. (eds) From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies. Lengerich: Pabst Science Publishers; 2007
66 Benedetti F et al. Emotional reactivity in chronic schizophrenia: structural and functional brain correlates and the influence of adverse childhood experiences. Psychol Med 2011; 41: 509-519
67 Lederbogen F et al. City living and urban upbringing affect neural social stress processing in humans. Nature 2011; 474: 498-501
68 Juckel G et al. Microglial activation in a neuroinflammational animal model of schizophrenia – a pilot study. Schizophr Res 2011; 131: 96-100
69 Meyer U. Developmental neuroinflammation and schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013; 42: 20-34
70 Marshall BJ. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Rev Infect Dis 1990; 12 (Suppl. 01) S87-S93
71 Lawn SD, Zumla AI. Tuberculosis. Lancet 2011; 378: 57-72
72 Müller N, Bechter K. The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings. Neurol Psychiatry Brain Res 2013; in revision
73 Carlson GD et al. Cerebral spinal fluid pressure: effects of body position and lumbar subarachnoid drainage in a canine model. Spine (Phila Pa 1976) 2003; 28: 119-122
74 Bechter K, Bogerts B. Inflammatory and Neuroimmunological Aspects in Psychiatric Disorders. Highlights of the 9th Psychoimmunology Expert Meeting: Neuropsychoimmunology of Psychoses. Immune and Inflammatory Aspects of Psychoses. In Vivo 2007; 21: 917-923
75 Hobbs JA. Detection of adeno-associated virus 2 and parvovirus B19 in the human dorsolateral prefrontal cortex. J Neurovirol 2006; 12: 190-199
76 Bechter K. Virus Infection as a Cause of Inflammation in Psychiatrie Disorders. in Halaris A, Leonard B, (eds) Inflammation in Psychiatry. Mod Trends Pharmacopsychiatry. Basel: S. Karger AG; 2013: 49-60
77 Yolken RH et al. Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. Schizophr Res 2011; 128: 61-65
78 Dickerson FB et al. Association of serum antibodies to herpes simplex virus 1 with cognitive deficits in individuals with schizophrenia. Arch Gen Psychiatry 2003; 60: 466-472
79 Dickerson FB et al. Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. Biol Psychiatry 2004; 55: 588-593
80 Dickerson F et al. Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortality. Schizophr Bull 2007; 33: 737-740
81 Bechter K, Bogerts B, Steiner J. Abstracts of the 10th Psychoimmunology Expert Meeting. Neurol Psychiatry Brain Res 2009; 16 (Suppl 1)
82 Drexhage RC et al. An activated set point of T-cell and monocyte inflammatory networks in recent-onset schizophrenia patients involves both pro- and anti-inflammatory forces. Int J Neuropsychopharmacol 2011; 14: 746-755
83 Brown DA, Sawchenko PE. Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J Comp Neurol 2007; 502: 236-260
84 Bartholomaus I et al. Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature 2009; 462: 94-98
85 Ransohoff RM. Immunology: In the beginning. Nature 2009; 462: 41-42
86 Lucchinetti CF et al. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365: 2188-2197
87 Perron H, Lang A. The human endogenous retrovirus link between genes and environment in multiple sclerosis and in multifactorial diseases associating neuroinflammation. Clin Rev Allergy Immunol 2010; 39: 51-61
88 Leboyer M et al. Human endogenous retrovirus type W (HERV-W) in schizophrenia: A new avenue of research at the gene-environment interface. World J Biol Psychiatry 2013; 14: 80-90
89 Oleszak EL et al. Theiler’s virus infection: a model for multiple sclerosis. Clin Microbiol Rev 2004; 17: 174-207
90 Pruss H et al. N-methyl-D-aspartate receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012; 72: 902-911
91 Klosterkötter J. Early detection of schizophrenia. Neurol Psychiatry Brain Res 2011; 17: 1-10
92 Reichenberg A et al. Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study. Am J Psychiatry 2010; 167: 160-169
93 Bayer TA, Falkai P, Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the „two hit hypothesis“. J Psychiatr Res 1999; 33: 543-548
94 Brown AS et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004; 61: 774-780
95 Meyer U et al. The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. J Neurosci 2006; 26: 4752-4762
96 Brown AS et al. AE Bennett Research Award. Prenatal rubella, premorbid abnormalities, and adult schizophrenia. Biol Psychiatry 2001; 49: 473-486
97 Brown AS. Further evidence of infectious insults in the pathogenesis and pathophysiology of schizophrenia. Am J Psychiatry 2011; 168: 764-766
98 Steiner J et al. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. World J Biol Psychiatry 2011; 13: 482-492
99 Steiner J et al. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res 2008; 42: 868-876
100 Doorduin J et al. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009; 50: 1801-1807
101 van Berckel BN et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008; 64: 820-822
102 Fusar-Poli P et al. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci Biobehav Rev 2011; 35: 1175-1185
103 Fusar-Poli P et al. Gray matter alterations related to P300 abnormalities in subjects at high risk for psychosis: longitudinal MRI-EEG study. Neuroimage 2011; 55: 320-328
104 Ho BC et al. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003; 60: 585-594
105 Davis KL et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003; 60: 443-456
106 Garver DL, Holcomb JA, Christensen JD. Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. Int J Neuropsychopharmacol 2008; 11: 49-61
107 Grant JK et al. Persistent adeno-associated virus 2 and parvovirus B19 sequences in post-mortem human cerebellum. Cerebellum 2009; 8: 490-498
108 Pugliese A et al. Parvovirus B19 and immune disorders. Cell Biochem Funct 2007; 25: 639-641
109 Schmitt A et al. Schizophrenia as a disorder of disconnectivity. Eur Arch Psychiatry Clin Neurosci 2011; 261 (Suppl. 02) 150-154
110 Uranova NA et al. Ultrastructural damage of capillaries in the neocortex in schizophrenia. World J Biol Psychiatry 2010; 11: 567-578
111 Nieratschker V, Nothen MM, Rietschel M. New Genetic Findings in Schizophrenia: Is there Still Room for the Dopamine Hypothesis of Schizophrenia?. Front Behav Neurosci 2010; 4: 23
112 Huber G, Gross G, Schüttler R. Schizophrenia. Clinical course and social psychiatric long term examinations of schizophrenic patients hospitalized in Bonn from 1945–1959. Monogr Gesamtgeb Psychiatr Psychiatry Ser 1979; 21: 1-399
113 Muller N et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159: 1029-1034
114 Laan W et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2010; 71: 520-527
115 Bechter K et al. Cerebrospinal fluid filtration in a case of schizophrenia related to “subclinical” Borna disease virus encephalitis. In: Müller N, (ed) Psychiatry, Psychoneuroimmunology and Viruses. Key Top Brain Res. Wien: Springer; 1999: 19-35
116 Knight JG et al. Rationale for a trial of immunosuppressive therapy in acute schizophrenia. Mol Psychiatry 2007; 12: 424-431
117 Ehrenreich H et al. Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis. Brain 2007; 130: 2577-2588
118 Ehrenreich H et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 2007; 12: 206-220
119 Ehrenreich H et al. Recombinant human erythropoietin in the treatment of human brain disease: focus on cognition. J Ren Nutr 2008; 18: 146-153
120 Oruch R et al. An intercalation mechanism as a mode of action exerted by psychotropic drugs: results of altered phospholipid substrate availabilities in membranes?. J Chem Biol 2010; 3: 67-88
121 Macdowell KS et al. Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammation. Int J Neuropsychopharmacol 2013; 16: 121-135
122 Sy M et al. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Am J Pathol 2011; 178: 2811-2822
123 Reiber H, Otto M, Bechter K. Crash Course: Cerebrospinal Fluid Diagnostics for Psychiatrists and Neurologists. Cerebrospinal fluid analysis for diagnosis of non-inflammatory, dementive and psychiatric diseases. Acta Neuropsychiatrica 2009; 21 (Suppl. 02) 58-61
124 Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 2001; 184: 101-122
125 Reiber H, Albaum W. Statistical evaluation of intrathecal protein synthesis in CSF/Serum quotient diagrams. Acta Neuropsychiatrica 2008; 20 (Suppl. 01) 48-49
126 Bechter K et al. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 2010; 44: 321-330
127 Maxeiner HG et al. Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders. Brain Behav Immun 2009; 23: 134-142
128 Kuehne LK et al. Cerebrospinal fluid neopterin is brain-derived and not associated with blood CSF barrier dysfunction. submitted
129 Muller N, Schwarz MJ. Immune System and Schizophrenia. Curr Immunol Rev 2010; 6: 213-220
130 Agnati LF, Bjelke B, Fuxe K. Volume versus wiring transmission in the brain: a new theoretical frame for neuropsychopharmacology. Med Res Rev 1995; 15: 33-45
131 Schwartz M, Shechter R. Protective autoimmunity functions by intracranial immunosurveillance to support the mind: The missing link between health and disease. Mol Psychiatry 2010; 15: 342-354
132 Weller RO et al. Lymphatic drainage of the brain and the pathophysiology of neurological disease. Acta Neuropathol 2009; 117: 1-14
133 Weller RO et al. Pathophysiology of the lymphatic drainage of the central nervous system: Implications for pathogenesis and therapy of multiple sclerosis. Pathophysiology 2010; 17: 295-306
134 Pollay M. The function and structure of the cerebrospinal fluid outflow system. Cerebrospinal Fluid Res 2010; 7: 9
135 Johanson CE et al. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal Fluid Res 2008; 5: 10
136 Cserr HF, Knopf PM. Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view. Immunol Today 1992; 13: 507-512
137 Andreasen N. Neuroimaging of schizophrenia: commentary. in Shenton ME, Turetsky BI, (ed) Understanding Neuropsychiatric Disorders – Insights from Neuroimaging. New York: Cambridge University Press; 2011: 88
138 Mulert C et al. Hearing voices: A role of interhemispheric auditory connectivity?. World J Biol Psychiatry 2012; 13: 153-158
139 Strik C et al. Intracranial oscillations of cerebrospinal fluid and blood flows: analysis with magnetic resonance imaging. J Magn Reson Imaging 2002; 15: 251-258
140 Bechter K. The peripheral cerebrospinal fluid outflow pathway – physiology and pathophysiology of CSF recirculation: a review and hypothesis. Neurol Psychiatry Brain Res 2011; 17: 51-66
141 Kong L et al. Neurological soft signs and gray matter changes: a longitudinal analysis in first-episode schizophrenia. Schizophr Res 2012; 134: 27-32
142 Meltzer HY, Crayton JW. Subterminal motor nerve abnormalities in psychotic patients. Nature 1974; 249: 373-375
143 Dale RC et al. Encephalitis lethargica syndrome: 20 new cases and evidence of basal ganglia autoimmunity. Brain 2004; 127: 21-33
144 Dalmau J. Anti-NMDAR and other synaptic mechanisms of autoimmune encephalitis. 8th International Congress on Autoimmunity. 2012
145 Dalmau J et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011; 10: 63-74
146 Irani SR, Vincent A. The expanding spectrum of clinically-distinctive, immunotherapy-responsive autoimmune encephalopathies. Arq Neuropsiquiatr 2012; 70: 300-304
147 Heuser M et al. Neurological signs and morphological cerebral changes in schizophrenia: An analysis of NSS subscales in patients with first episode psychosis. Psychiatry Res 2011; 192: 69-76
148 Schwartz M, Kipnis J. A conceptual revolution in the relationships between the brain and immunity. Brain Behav Immun 2011; 25: 817-819
149 Reiber H. Cerebrospinal fluid – physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler 1998; 4: 99-107
150 Schmitt M et al. Spreading of Acute Myeloid Leukemia Cells by Trafficking along the Peripheral Outflow Pathway of Cerebrospinal Fluid. Anticancer Res 2011; 31: 2343-2345
151 Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr Bull 2009; 35: 528-548
152 Engelhardt B, Sorokin L. The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction. semin Immunopathol 2009; 31: 497-511
153 Bechmann J et al. What is the blood-brain barrier (not)?. Trends Immunol 2007; 28: 5-11
154 Wolburg H, Paulus W. Choroid plexus: biology and pathology. Acta Neuropathol 2010; 119: 75-88
155 Reiber H. Flow rate of cerebrospinal fluid (CSF) – a concept common to normal blood-CSF barrier function and to dysfunktion in neurological diseases. J Neurol Sci 1994; 122: 189-203